CAMBRIDGE, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on April 21, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 375,000 restricted stock unit awards (RSUs) to four new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan. The RSUs are being granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule5635(c)(4).

See more here:
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)